Abortion pill approval moves forward, but legal gaps leave long road ahead

The government has officially announced plans to introduce mifepristone domestically in the first quarter of next year, accelerating its push to bring the drug into the regulated system. But seven years of legislative inaction have left a tangle of legal and medical obstacles that must be resolved before the drug can take hold in clinical practice.

The issues go well beyond a simple debate over whether to allow the drug. Critics say the National Assembly must urgently pass replacement legislation to address a web of structural questions: whether administrative approval without a legal amendment is lawful, whether in-clinic administration should be mandatory, how to protect physicians' right to decline on conscientious grounds, whether national health insurance should cover the drug, and how to handle the spousal consent provision still on the books.

The government's decision to fast-track drug approval stems from a pressing need to protect women's health from counterfeit and unregulated pills circulating on the black market.

Minister of Gender Equality and Family Won Min-kyung said Tuesday in a radio interview that the government could no longer hesitate. "Serious harm to women's health has resulted from the consumption of counterfeit drugs and misuse, because the medication has not been permitted and has been distributed illegally," she said. "Since both the health of the fetus and women, as well as the right to self-determination, are all important fundamental rights, we will actively review national health insurance coverage and bring this into a safe public healthcare system."

But the very first step — approval by the Ministry of Food and Drug Safety acting alone — already faces legal challenge. Article 2 of the current Maternal and Child Health Act still defines induced abortion exclusively as a "surgical" procedure. Critics argue that allowing a new method through pharmaceutical approval alone, without the National Assembly first amending the law to include "medical methods such as medication or surgery," in effect changes the regulatory framework through administrative action — an overreach.

The Ministry of Government Legislation and the broader administration push back, arguing that the Constitutional Court's ruling that the criminal ban on abortion was unconstitutional rendered those criminal penalties void, and that no provision of the Pharmaceutical Affairs Act explicitly prohibits such approval. On that basis, they contend that product approval following a safety and efficacy review is possible even before the National Assembly amends the law.

A heated debate has also erupted over where and how the drug should be administered. International guidelines, including those of WHO, increasingly recognize self-managed use at home under certain conditions, but South Korea's medical community has cited the risk of side effects in insisting that prescription, dispensing, and administration must take place within a medical facility under direct supervision.

The directly elected Korean Association of Obstetrics and Gynecology Clinic Physicians warned in a statement that mifepristone "must not be oversimplified as a drug with few side effects that is easy to take." The group cited US Food and Drug Administration clinical trial data showing that 85 percent of patients who took the drug in combination experienced adverse reactions, with a 5.5 percent rate of severe bleeding — defined as a drop in hemoglobin of 2 g/dL or more — and roughly 1 percent requiring surgical evacuation of the uterus due to incomplete abortion.

The group also warned that "if an ectopic pregnancy is not ruled out in advance by ultrasound, fallopian tube rupture can cause massive intra-abdominal hemorrhage and acute death," and insisted that "the state must not shift the risks and legal liability onto frontline medical staff and patients under the name of 'physician discretion' without clear standards."

The right of physicians to decline on conscientious grounds — and the legal protections that would accompany it — is another flashpoint. The medical community has consistently called for legislation guaranteeing the right of doctors who object on religious or ethical grounds to refuse to prescribe the drug.

Three major obstetrics and gynecology organizations — the Korean Society of Obstetrics and Gynecology, the Korean Association of Obstetricians and Gynecologists, and the directly elected clinic physicians' association — issued a joint statement expressing support for a national management system to curb illegal distribution, while insisting that institutional safeguards must come first.

The groups urged that "the right of physicians who choose not to participate in prescribing based on personal conviction must be respected, while procedures for rapid referral to necessary care must be clearly written into law." They also called for safety management systems, compensation measures, and legal protections for medical personnel to be put in place simultaneously, "so that healthcare workers who participate in prescribing and administering the drug are not left in criminal legal uncertainty while criminal law reform remains incomplete."

Minister Won signaled a different view, saying that "given the intent of the constitutional incompatibility ruling, there is little concern about physicians being punished, and if a doctor finds it difficult to provide care, they can refer the patient to another institution."

Beyond national health insurance coverage — which will determine how accessible the treatment actually is — pre-consultation and waiting period requirements, as well as the spousal consent provision, also remain major unresolved issues.

If the drug is launched without insurance coverage, its high cost could push vulnerable women back toward illegal online sources, making coverage essential. The Ministry of Health and Welfare has signaled a cautious stance, however, saying whether to cover the drug remains to be seen pending a pharmaceutical company's application and broader social consensus.

In addition, the spousal consent requirement still embedded in Article 14 of the Maternal and Child Health Act — which restricts women's right to self-determination — is widely seen as out of step with reality and in urgent need of repeal. Views on pre-consultation and waiting period requirements are sharply divided: some see them as tools to support careful decision-making, while others warn they could become administrative barriers that unfairly delay access to timely care.

The National Assembly Research Service also weighed in recently, noting in a report that "product approval by the Ministry of Food and Drug Safety is merely approval for use where safety and efficacy have been demonstrated, and cannot substitute for the legally permitted gestational limits, grounds, and procedures for abortion."

The report said that "since pharmaceutical product approval is not a disposition that determines the legality of a specific abortion method, product approval cannot be restricted on the grounds of a legislative gap — but the regulatory framework for abortion must be clearly established through legislation," and stressed the need for the National Assembly to simultaneously advance replacement legislation amending the Maternal and Child Health Act and the Criminal Act.

Ultimately, the announcement of the drug's introduction is only the starting point of an institutionalization process stalled for seven years. Calls are growing for the National Assembly to fulfill its legislative duty without delay — amending the Maternal and Child Health Act and the Criminal Act — to ensure full protection of women's health rights and to create an environment in which medical professionals can practice without fear, rather than relying on administrative drug approval alone.